Pfizer Animal Health recently announced FDA approval for its A180 (danofloxacin mesylate), a new antimicrobial treatment for bovine respiratory disease (BRD) associated with Mannheimia (Pasteurella) haemolytica and Pasteurella multocida in beef cattle.
Developed by Pfizer specifically and exclusively for livestock use, A180 gives beef producers and veterinarians what they have been looking for--an effective solution to BRD treatment, with a unique four-day withdrawal period. A180 is administered as a concentrated low-volume subcutaneous injection (1.5 mL per 100 lbs. bodyweight) that is easy on cattle and offers convenience with less medical waste.
"A180 is an important part of Pfizer's global anti-infective product line," said Jim Lee, vice president global marketing for Pfizer Animal Health. "Its availability only by prescription from a licensed veterinarian for the treatment of BRD will provide a strong foundation for responsible use."
A180 is manufactured in the United States to Pfizer quality production standards. A180 is not for use in cattle intended for dairy production, nor for calves to be processed for veal, and is not intended for human use.
For more information, circle X on the Reader Reply Coupon, call your local veterinarian, or visit www.pfizer.com.